Streetbeat News

Products Services

TYRA

Tyra Biosciences has announced preclinical proof-of-concept results for TYRA-300, showing increased long bone length and effective binding against HCH altered protein. The company is on track to submit an ACH Investigational New Drug Application in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 8:06 pm

MAXN

Maxeon Solar Technologies has been granted U.S. Patent #12027636 for a new protection coating for solar cell wafers. This patent could enhance the company's technological edge and product offerings in the solar energy market.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 8:03 pm

GBTC

IBIT

Spot Bitcoin and Ethereum ETFs are expected to drive the next phase of the bull cycle. Spot Bitcoin ETFs have seen significant inflows, while Grayscale Bitcoin Trust has experienced outflows. Spot Ethereum ETFs are anticipated to be approved soon, with substantial inflows predicted.

Portfolio Pulse from Khyathi Dalal

July 02, 2024 | 7:58 pm

TEM

Tempus AI Inc (NASDAQ:TEM) shares rose by 7.45% to $35.82 after the company announced it was granted Advanced Diagnostic Laboratory Test (ADLT) status for its next-generation sequencing assay by the Centers for Medicare & Medicaid Services (CMS). This designation supports Tempus's mission to enhance patient care through precision medicine.

Portfolio Pulse from Henry Khederian

July 02, 2024 | 7:36 pm

CTSO

CytoSorbents Corp (NASDAQ:CTSO) shares surged by 21% to $0.85 after securing a $20 million credit facility with Avenue Capital Group. The funds will support the CytoSorb® franchise and aid in FDA and Health Canada applications for DrugSorb™-ATR.

Portfolio Pulse from Henry Khederian

July 02, 2024 | 7:31 pm

BYDDY

TSLA

BYD Company (OTC:BYDDY) saw a 21% increase in Q2 EV sales, selling 426,039 units and narrowing the gap with Tesla (NASDAQ:TSLA). BYD also launched five new electric models in Tunisia and entered a strategic partnership with Ayvens SA to expand in Europe. Tesla is expected to report a 6% decline in Q2 deliveries.

Portfolio Pulse from Vaishali Prayag

July 02, 2024 | 7:27 pm

PCRX

Pacira BioSciences shares are trading lower after the FDA approved a generic version of Exparel.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 7:18 pm

AAPL

AMZN

MSFT

Apple, Microsoft, and Amazon shares hit new all-time highs driven by optimism around AI advancements. Apple's stock surged due to expectations from its Worldwide Developers Conference, Microsoft benefited from its investment in OpenAI, and Amazon gained from its AI strategy and AWS leadership.

Portfolio Pulse from Adam Eckert

July 02, 2024 | 7:16 pm

PCRX

The U.S. FDA has approved a generic version of Exparel (Bupivacaine Liposome), a non-opioid used for post-surgery local anesthesia. The approval was granted to Hengrui Pharma.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 7:12 pm

TIXT

TU

Telus is investing a total of $21.1 million in various regions of Canada to deploy and update its networks. The investments include $6.6 million in the North Shore region, $6 million in the Gaspé Peninsula, and $8.5 million in the Lower St. Lawrence.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 7:06 pm